Surrogate to predict overall survival in patients with BRAF V600E-mutant colorectal cancer treated with BRAF inhibitor combinations

Background: The BRAF V600E mutation, found in up to 12% of patients with metastatic colorectal cancer, is associated with aggressive disease and poor response to standard chemotherapy. However, the advent of BRAF inhibitors has led to improved clinical outcomes and survival. While surrogate endpoint...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	J. Ros, V. Navarro, G. Villacampa, I. Baraibar, F. Salvà, M. Rodriguez, C. Vaghi, A. Garcia, A. Alcaraz, J. Tabernero, E. Élez, R. Dienstmann
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Elsevier 2025-09-01
Σειρά:	ESMO Gastrointestinal Oncology
Θέματα:	surrogate markers BRAF mutation colorectal cancer targeted therapy BRAF inhibitor
Διαθέσιμο Online:	http://www.sciencedirect.com/science/article/pii/S2949819825000949
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!